Tandem Diabetes Care, Inc. Announces 2024 Annual Meeting of Stockholders

Ticker: TNDM · Form: DEF 14A · Filed: Apr 9, 2024 · CIK: 1438133

Tandem Diabetes Care Inc DEF 14A Filing Summary
FieldDetail
CompanyTandem Diabetes Care Inc (TNDM)
Form TypeDEF 14A
Filed DateApr 9, 2024
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$750, $25.1 million, $3.5 m
Sentimentneutral

Sentiment: neutral

Topics: Tandem Diabetes Care, TNDM, DEF 14A, Annual Meeting, Proxy Statement

TL;DR

<b>Tandem Diabetes Care, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 22, 2024, to elect directors and vote on equity plans.</b>

AI Summary

TANDEM DIABETES CARE INC (TNDM) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. Annual Meeting scheduled for May 22, 2024, at 3:00 p.m. Pacific Time. Meeting will be held virtually via live internet webcast at www.virtualshareholdermeeting.com/TNDM2024. Key agenda items include the election of nine directors for a one-year term. Stockholders will vote on approving the Company's 2013 Employee Stock Purchase Plan, as Amended. Approval of the Company's 2023 Long-Term Incentive Plan is also on the agenda.

Why It Matters

For investors and stakeholders tracking TANDEM DIABETES CARE INC, this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the agenda and proposals for the upcoming annual meeting. Shareholders have the opportunity to vote on director elections and amendments to key employee incentive and stock purchase plans.

Risk Assessment

Risk Level: low — TANDEM DIABETES CARE INC shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.

Analyst Insight

Review the director nominees and the proposed amendments to the Employee Stock Purchase Plan and Long-Term Incentive Plan before the May 22, 2024 meeting.

Key Numbers

  • 9 — Directors to be elected (Proposal 1: To elect nine directors)
  • 2013 — Employee Stock Purchase Plan Year (Proposal 2: To approve the Company’s 2013 Employee Stock Purchase Plan, as Amended)
  • 2023 — Long-Term Incentive Plan Year (Proposal 3: To approve the Company’s 2023 Long-Term Incentive P)

Key Players & Entities

  • TANDEM DIABETES CARE INC (company) — Registrant name
  • May 22, 2024 (date) — Date of Annual Meeting
  • 3:00 p.m. Pacific Time (time) — Time of Annual Meeting
  • www.virtualshareholdermeeting.com/TNDM2024 (url) — Web address for the virtual meeting
  • 2013 Employee Stock Purchase Plan, as Amended (plan) — Plan to be approved
  • 2023 Long-Term Incentive Plan (plan) — Plan to be approved
  • San Diego (location) — Company's business address city
  • DE (location) — State of incorporation

FAQ

When did TANDEM DIABETES CARE INC file this DEF 14A?

TANDEM DIABETES CARE INC filed this Proxy Statement (DEF 14A) with the SEC on April 9, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by TANDEM DIABETES CARE INC (TNDM).

Where can I read the original DEF 14A filing from TANDEM DIABETES CARE INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by TANDEM DIABETES CARE INC.

What are the key takeaways from TANDEM DIABETES CARE INC's DEF 14A?

TANDEM DIABETES CARE INC filed this DEF 14A on April 9, 2024. Key takeaways: Annual Meeting scheduled for May 22, 2024, at 3:00 p.m. Pacific Time.. Meeting will be held virtually via live internet webcast at www.virtualshareholdermeeting.com/TNDM2024.. Key agenda items include the election of nine directors for a one-year term..

Is TANDEM DIABETES CARE INC a risky investment based on this filing?

Based on this DEF 14A, TANDEM DIABETES CARE INC presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.

What should investors do after reading TANDEM DIABETES CARE INC's DEF 14A?

Review the director nominees and the proposed amendments to the Employee Stock Purchase Plan and Long-Term Incentive Plan before the May 22, 2024 meeting. The overall sentiment from this filing is neutral.

How does TANDEM DIABETES CARE INC compare to its industry peers?

Tandem Diabetes Care, Inc. operates in the medical device industry, specifically focusing on diabetes management technology.

Are there regulatory concerns for TANDEM DIABETES CARE INC?

This filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.

Risk Factors

  • General Disclosure [low — regulatory]: This filing is a proxy statement (DEF 14A) for the annual meeting of stockholders.

Industry Context

Tandem Diabetes Care, Inc. operates in the medical device industry, specifically focusing on diabetes management technology.

Regulatory Implications

This filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.

What Investors Should Do

  1. Review the list of director nominees and their qualifications.
  2. Understand the proposed amendments to the 2013 Employee Stock Purchase Plan.
  3. Evaluate the details of the 2023 Long-Term Incentive Plan.

Key Dates

  • 2024-05-22: 2024 Annual Meeting of Stockholders — Election of directors and vote on equity plans.

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 Annual Meeting, detailing proposals for shareholder vote.

Filing Stats: 4,714 words · 19 min read · ~16 pages · Grade level 12.9 · Accepted 2024-04-09 16:54:37

Key Financial Figures

  • $750 — 2024 Proxy Statement Proxy Summary ~$750* MILLION worldwide sales ~7% INCREA
  • $25.1 million — nclude the effect of sales deferrals of $25.1 million and $3.5 million, respectively. This re
  • $3.5 m — of sales deferrals of $25.1 million and $3.5 million, respectively. This relates to th

Filing Documents

Executive Compensation Highlights

Executive Compensation Highlights 4 General Information 5 Notice of Internet Availability of Proxy Materials 5 Stockholders Entitled to Vote 5 How to Vote 5 Change of Vote or Revocation of Proxy 5 Attending the Annual Meeting 6 Technical Assistance for the Annual Meeting 6 Quorum, Abstentions and Broker Non-Votes 6 Cost of Soliciting Proxies 6 Announcement of Voting Results 6 Contact Information for Questions 6 Caution Concerning Forward-Looking Statements 6 Management Proposals 7 Proposal 1: Election of Directors 7 Proposal 2: 2013 Employee Stock Purchase Plan as Amended 13 Proposal 3 : 2 023 Long-Term Incentive Plan as Amended 19 Proposal 4 : Say-on-Pay 27 Proposal 5 : Appointment of Independent Registered Public Accounting Firm 29 Stock Ownership 31 Principal Stockholders 31 Directors and Executive Officers 32 Corporate Governance 33 Corporate Governance Guidelines 33 Codes of Ethics and Conduct 33 Board Role in Risk Oversight 33 Director Nomination Process 34 Board Experience 35 Board Diversity 36 Director Independence, Agreements and Relationships 37 Board Committees 38 Board Meetings 41 Board Leadership Structure 42 Stockholder Engagement 42 Commitment to Environmental, Social and Governance Priorities 43 Compensation Discussion and Analysis 45 Executive Summary 45 Executive Officers 49 Compensation Philosophy and Objectives 51 Compensation Elements 54 Compensation Governance 60

Executive Compensation Tables

Executive Compensation Tables 65 Director Compensation 74 Compensation Committee Report 77 Audit Committee Report 78 Additional Information 79 Appendix A A- 1 Appendix B B- 1 Proxy Summary Proxy Summary Our Annual Meeting of Stockholders Will Take Place Virtually DATE May 22, 2024 TIME 3:00 p.m. Pacific time MEETING WEB ADDRESS www.virtualshareholdermeeting.com/TNDM2024 This summary provides highlights of information contained in this Proxy Statement. It does not contain all of the information that you should consider before voting. We encourage you to read the entire Proxy Statement. For more complete information regarding our 2023 financial and operating performance, please read our 2023 Annual Report on Form 10-K, or the Annual Report. Your vote is very important. Whether or not you plan to virtually attend the Annual Meeting, we encourage you to submit your proxy or voting instructions as soon as possible. You may submit your proxy by internet, telephone or mail. To vote by the internet before the meeting, visit www.proxyvote.com. Vote by 11:59 p.m. Eastern Time on May 21, 2024 for shares held directly and by 11:59 p.m. Eastern Time on May 20, 2024 for shares held in a Plan. To vote by the internet during the meeting, visit www.virtualshareholdermeeting.com/TNDM2024 . Have your notice or proxy card on hand and follow the instructions. To vote by telephone, call 1-800-690-6903 by 11:59 p.m. Eastern Time on May 21, 2024 for shares held directly and by 11:59 p.m. Eastern Time on May 20, 2024 for shares held in a Plan. Have your notice or proxy card on hand and follow the instructions. To vote by mail, mark, sign, date and return your proxy card in the postage-paid, pre-addressed envelope we have provided, or send it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. Items to be Considered and Board Recommendations Item Board's Voting Recommendation Page Reference PROPOSAL 1 To elect nine directo

Executive Compensation Practice Highlights

Executive Compensation Practice Highlights We Pay for Performance We Seek to Mitigate Compensation Risk Mix of diversified long- and short-term performance metrics to incentivize and reward the achievement of our operational and long-term business strategy objectives Annual compensation assessment; retain independent compensation consultant; independent compensation committee Long-term equity incentive awards feature a three-year vesting schedule, with the CEO's mix of awards being 50% restricted stock units and 50% performance stock units Clawback policy covering both cash and equity incentive compensation No single-trigger cash severance or automatic vesting of equity awards based solely upon a change of control of the Company Stock ownership guidelines for directors and members of executive management For additional information, see the "Compensation Discussion and Analysis" section of this Proxy Statement, as well as the Summary Compensation Table and related compensation tables, notes and narrative discussion. Tandem Diabetes Care 4 2024 Proxy Statement General Information GENERAL INFORMATION These proxy materials are being furnished in connection with the solicitation of proxies by the Board of Directors of Tandem Diabetes Care, Inc. for use during the 2024 annual meeting of stockholders, or the Annual Meeting, to be held on Wednesday, May 22, 2024, at 3:00 p.m. Pacific time, and at any adjournment or postponement thereof. Tandem Diabetes Care, Inc. is sometimes referred to herein as "we," "us," "our" or the "Company." Notice of Internet Availability of Proxy Materials This Proxy Statement, together with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, or the Annual Report, filed with the U.S. Securities and Exchange Commission, or SEC, on February 21, 2024, is being made available to stockholders at www.proxyvote.com. The Annual Report is not a part of the proxy solicitation material. This Proxy Sta

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.